Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Research Question:
Is SEA-BCMA tan effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur?

Basic Study Information

Purpose:
This trial will study SEA-BCMA, a monoclonal antibody, to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SEA-BCMA should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.

Location: University of Rochester Medical Center
Study Reference #: IMMY18128

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Stephanie Short
Phone: (585) 276-7885
Email: Stephanie_Short@URMC.Rochester.edu

Additional Study Details

Return to Search